The shikimate pathway is essential for production of a plethora of aromatic compounds in plants, bacteria, and fungi. Seven enzymes of the shikimate pathway catalyze sequential conversion of erythrose 4-phosphate and phosphoenol pyruvate to chorismate. Chorismate is then used as a substrate for other pathways that culminate in production of folates, ubiquinone, napthoquinones, and the aromatic amino acids tryptophan, phenylalanine, and tyrosine. The shikimate pathway is absent from animals and present in the apicomplexan parasites Toxoplasma gondii, Plasmodium falciparum, and Cryptosporidium parvum. Inhibition of the pathway by glyphosate is effective in controlling growth of these parasites. These findings emphasize the potential benefits of developing additional effective inhibitors of the shikimate pathway. Such inhibitors may function as broad-spectrum antimicrobial agents that are effective against bacterial and fungal pathogens and apicomplexan parasites.
Overview of the Shikimate Pathway and Its Branches, Derivatives, and Organization
Characterization of the shikimate pathway of apicomplexan parasites is of special interest because the pathway is absent from animals but apparently essential for survival of the parasites [1, 2] . Thus, understanding the shikimate pathway in these organisms may assist in the development of new antiparasitic agents. The plethora of information available on the shikimate pathway of other organisms (bacteria, fungi, and plants) provides a starting point for these studies. However, existing data reveal differences in shikimate pathways of bacteria, fungi, and plants and suggest many possible modes of regulation and inhibition of the pathway. It remains to be seen whether the pathway in apicomplexan parasites provides yet more diversity.
The shikimate pathway operates in the cytosol of bacteria and fungi, but in plants it is also known to operate in plastid organelles. The pathway utilizes phosphoenol pyruvate and erythrose 4-phosphate to produce chorismate through seven catalytic steps [3, 4] (figure 1). It is a pathway with multiple branches. While branches exist from various intermediate products of the pathway, chorismate represents the major branch point, and various branches give rise to many end products. Derivatives of chorismate include tryptophan via an anthranilate intermediate [3, 4] , phenylalanine and tyrosine via prephenate or arogenate [3] [4] [5] , and vitamin K and metal chelators containing dihydroxybenzoic acid, such as enterochelin, via isochorismate [3, 4] . Chorismate also is used for production of ubiquinone and p-aminobenzoic acid (PABA), which is converted into folates. The shikimate pathway also gives rise to many secondary metabo- Figure 1 . The shikimate pathway and major branches from chorismate. A, The shikimate pathway catalyses the conversion of phosphoenoly pyruvate and erythrose 4-phosphate to chorismate by 7 enzymatic steps (boxed). Major branches from chorismate include ubiquinone synthesis, which is dependent on 8 enzymes (boxed) (B); folate synthesis, which is dependent on 6 enzymes (boxed) (C); tryptophan synthesis, which is dependent on 7 enzymes (boxed) (D); phenylalanine and tyrosine synthesis, which occur by separate pathways that branch from prephenate and involve the action of a further 5 enzymes (boxed) (E). Further branches exist from chorismate in certain organisms, including isoprenoid synthesis, and from other intermediates, such as quinate synthesis from dehydroquinate. There is currently direct evidence only for the branch leading to folates in apicomplexan parasites. * There are many variations and subtleties in tyrosine and phenylalamine synthesis in different species.
lites, including flavanones and napthoquinones [6] , and there is an alternative version of the pathway with aminated intermediates that give rise to aminohydroxybenzoate (AHBA), the precursor of the ansamycin antibiotics [7] . Our recent work on apicomplexans has demonstrated a role for the shikimate pathway in the production of PABA and folates in these organisms [1] .
Twenty percent of the carbon derived from carbohydrate catabolism is utilized in the shikimate pathway in certain organisms [8] ; therefore, it is a major part of their metabolism. Animals lack the shikimate pathway enzymes and, with the exception of dihydrofolate reductase (DHFR), lack enzymes downstream of chorismate. These observations suggested to us that this pathway and its branches in apicomplexan parasites might provide a number of interrelated targets for antiparasitic agents [1] .
The shikimate pathway is a viable herbicide target [9] . Specifically, 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase, the sixth enzyme in the pathway, is the target for glyphosate, a widely used herbicide (Roundup; Sigma) [3, 4, 9] . The compound also inhibits EPSP synthase of Toxoplasma gondii and the growth of T. gondii, Plasmodium falciparum, and Cryptosporidium parvum [1] . A number of other compounds that inhibit various other enzymes in the shikimate pathway have been described, and some inhibit the growth of bacteria [10] . It is surprising that none of these has been developed commercially. Two of these compounds, the fluorinated analogues of shikimate (6R)-6-fluoroshikimate and (6S)-6-fluoroshikimate, inhibit the growth of P. falciparum in vitro, presumably through competitive inhibition of the shikimate pathway [2] .
Genes encoding many shikimate pathway enzymes have been cloned from various bacteria, plants, and fungi. In contrast, chorismate synthase genes of T. gondii and P. falciparum are the only apicomplexan representatives that have been cloned and sequenced [1] . In addition, we have recently obtained evidence for the presence of chorismate synthase in Eimeria bovis, Plasmodium vivax, and C. parvum (unpublished data).
Our recent demonstration that the shikimate pathway is important for the survival of a number of apicomplexans has raised a number of interesting questions that we and others are currently addressing. First, since the shikimate pathway is generally operative in the plastid of plants [3, 4] , we are interested in whether some or all of it occurs in the plastid-like organelle of apicomplexans. Second, we are interested in how the apicomplexan shikimate pathway is regulated, particularly as this may provide clues regarding the best potential targets for new antimicrobial agents. Third, what is the importance of branches of the shikimate pathway for various stages of the life cycles of apicomplexan parasites, including latent stages?
The Need for New Antimicrobial Agents for Treatment of Apicomplexan Parasites
The phylum Apicomplexa consists of a large number of protozoa, including species of Toxoplasma, Plasmodium, Eimeria, Theileria, Cryptosporidium, and Babesia. These parasites are responsible for a variety of diseases in humans and livestock. For example, T. gondii, a very common parasite, causes ocular and neurologic lesions and can result in systemic disease and death when acquired in utero [11] . It has been estimated to cost more than two billion dollars per annum to care for children born with congenital infection in the United States [12] . Moreover, toxoplasmosis is a devastating disease in those who are immunocompromised due to AIDS, chemotherapy, malignancy, transplantation, or autoimmune diseases and the involved therapies [11] .
The most effective chemotherapy for toxoplasmosis currently comprises the combination of the antifolate agents pyrimethamine and sulfadiazine. These are both associated with significant adverse reactions. Pyrimethamine inhibits the action of DHFR and thus the production of tetrahydrofolate, which is required for a number of reactions. Since DHFR is present in humans, pyrimethamine-induced depletion of folate cofactors can lead to bone marrow suppression. Sulfadiazine can cause allergy and is commonly poorly tolerated, which results in problems with compliance. Furthermore, this combination therapy acts only on the rapidly dividing tachyzoite stage associated with active disease and does not affect the quiescent bradyzoite stage that forms cysts throughout the body. Thus the encysted bradyzoite forms remain a reservoir of infection even in treated individuals and can give rise to repeated disease reactivation. This is especially evident in congenitally infected and immunocompromised individuals. Disease reactivation is common in the eye and brain, where the consequences can be serious. Therapy is often required on multiple occasions and for long periods of time [11] .
Malaria is caused by the apicomplexan parasites of the genus Plasmodium. The four common species of Plasmodium (P. falciparum, P. malariae, P. vivax, and P. ovale) infect millions of people and account for the death of more than 2 million children annually. The emergence of drug resistance has limited the useful life span of many antimalarial medicines. Current treatments include inhibitors, such as pyrimethamine and sulfadoxine, of the folate synthetic pathway [13] .
C. parvum is another apicomplexan parasite that causes disease in humans and livestock. It causes debilitating and lifethreatening diarrheal illness in patients infected with human immunodeficiency virus. C. parvum infection can also occur in epidemics, in which it is most severe in the young and elderly. There is currently no effective treatment for the disease caused by this parasite [14, 15] .
An advantage of developing agents that target the shikimate pathway is their potential to inhibit the growth of bacterial and fungal pathogens and apicomplexan parasites. There are growing concerns associated with the emergence of multidrugresistant bacteria, such as Staphylococcus aureus, as well as a number of enterococci, Streptococcus pneumoniae, and enteric gram-negative bacteria [16] . In addition, there is now considerable worry about the increased occurrence of multidrug resistance among Mycobacterium tuberculosis, Salmonella typhi, Shi-gella species, and Neisseria gonorrhoeae [17] . Furthermore, in immunocompromised patients, multiple infections with fungi and a variety of different classes of organisms, including mycobacteria and apicomplexan parasites, may occur. There is thus great need for the development of new antimicrobial agents, and one that targeted several of these diseases would be especially beneficial.
Evidence for the Shikimate Pathway in Apicomplexan Parasites
Chemotherapeutic, biochemical (figures 2, 3), and genetic (figure 4) evidence has been obtained for shikimate pathway enzymes in apicomplexan parasites, including T. gondii, P. falciparum, and C. parvum [1] . In addition, we have completed sequencing the P. vivax aroC encoding chorismate synthase and included it in the multisequence alignment in figure 4 (GenBank accession number AF451277).
The first evidence we obtained for the presence of the shikimate pathway in T. gondii was the ability of glyphosate to restrict growth of T. gondii in vitro (figures 2A, 3). As this inhibition was overcome by the addition of PABA to treated cultures, it is likely that the shikimate pathway is important for supply of folate precursors in this parasite. Additional control experiments demonstrated that the addition of PABA could reverse the inhibitory effect of sulfadiazine. Sulfadiazine inhibits the action of dihy- ]uracil uptake by the parasite (3.12 mM glyphosate vs. none, P , :002). RH, T. gondii tachyzoites of the RH strain; P/S, pyrimethamine and sulfadiazine. Glyphosate toxicity for a variety of cell lines, including HFF (dividing cells), bovine kidney cells (MDBK), and erythrocytes were assessed. The concentrations used were not toxic. B, p-aminobenzoic acid (PABA) rescue of glyphosate growth inhibition. Added PABA reversed the effects of glyphosate and sulfadiazine (S) but not pyrimethamine (P). C, Inhibition of 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase enzyme activity by 1 mM glyphosate. Parasite extracts were produced at 4 C. D, In vivo activity of glyphosate and pyrimethamine against T. gondii. ND4 mice were infected intraperitoneally with T. gondii tachyzoites (RH strain) and immediately treated orally with glyphosate alone (100 mg/kg/day; no surviving mice by day 9), with pyrimethamine alone (12.5 mg/kg/day; 10% surviving mice by day 9), or with these agents combined at the specified concentrations, or they were left untreated (0% survival at 9 days). Treatment of mice with either drug alone was not sufficient to prevent death (i.e., was similar to that of control mice). In contrast, 50% of mice administered glyphosate and pyrimethamine simultaneously survived infection (at 7 days after infection, P , :05). Results were similar in 2 replicate experiments; the data shown are a composite of these experiments (10-12 mice/group). PABA and folate were administered ad libitum in the diet. Reprinted with permission from [1] . dropteroate synthase and thus the incorporation of PABA into the folate biosynthetic pathway. As expected, however, addition of PABA to pyrimethamine-treated cultures had no antagonistic effect on efficacy of pyrimethamine. This is because pyrimethamine exerts its effect later in the pathway by inhibiting dihydrofolate reductase (figure 2B). Confirmation of a T. gondii EPSP synthase, which can be inhibited by glyphosate, was obtained by measuring enzyme activity in crude T. gondii extracts (figure 2C): 1 mM glyphosate inhibited 85% of the EPSP synthase activity.
Ability of glyphosate to inhibit growth in vitro of asexual erythrocytic forms of P. falciparum also was tested. At a concentration of 1 mM, glyphosate completely inhibited parasite growth, an effect that could be abrogated by treatment with PABA or folate ( figure 3A) . Similarly, growth in vitro of C. parvum was curtailed by glyphosate (figure 3B), although in this case, addition of PABA to cultures did not abrogate inhibition (data not shown). This last observation suggests that the shikimate pathway is absolutely essential in this parasite, presumably providing precursors for biochemical pathways other than the one that leads to folates. Alternatively, a lack of effect from added PABA may simply reflect poor transport of the compound into C. parvum. The ability of glyphosate to act in synergy with sulfadiazine and pyrimethamine, which interfere with folate synthesis by inhibiting dihydropteroate synthase and DHFR, respectively, was tested in vitro. Glyphosate appeared to act synergistically with both of these compounds in inhibiting in vitro growth of T. gondii (table 1) .
Glyphosate has had extensive toxicological testing and has been defined as "practically non-toxic." As such, it requires in excess of 2000 mg/kg to cause acute toxicity in mammals [18] . Thus the effect of glyphosate on apicomplexan parasites was assessed by use of a murine model of toxoplasmosis. These experiments found that although glyphosate had no effect when administered alone, it significantly reduced mortality when given in combination with low doses of pyrimethamine ( figure  2D ). This demonstrates that inhibitors of EPSP synthase can act in synergy with conventional antifolates and may be a useful addition to the agents used against apicomplexan parasites. This approach may have great benefit in treating drug-resistant malaria as we also found that glyphosate is equally effective in vitro against both pyrimethamine-sensitive and pyrimethamine-resistant P. falciparum lines.
More recently, (6R) and (6S)-6-fluoroshikimate have each been shown to inhibit the growth of P. falciparum in vitro [2] . The effect of (6R)-6-fluoroshikimate was ablated by the addition of aromatic amino acids (phenylalanine, tyrosine, tryptophan), PABA, and para-hydroxybenzoate (PHBA). In contrast, addition of aromatic amino acids and PHBA or of aromatic amino acids alone was not sufficient to ablate the effects of the (6R)-6-fluoroshikimate. The effect of PABA alone was not tested in these experiments, making it difficult to determine if PHBA and the aromatic amino acids are necessary to reverse the effects of this inhibitor [2] .
EPSP synthase activity is detectable in crude extracts of T. gondii, and low levels of chorismate synthase can also be measured in crude T. gondii extracts by use of an anaerobic assay [1, 19] . Further studies detected 3-dehydroquinate dehydratase and shikimate kinase in T. gondii lysates (3.0 and 1.6 mU/mg protein, respectively). 3-dehydroquinate dehydra- Figure 3 . Evidence for the shikimate pathway in Plasmodium falciparum and Cryptosporidium parvum. A, Functional evidence for the shikimate pathway in P. falciparum. Glyphosate inhibition of in vitro growth of asexual erythrocytic forms and p-aminobenzoic acid (PABA) and folate (FA) antagonism of growth inhibition. Glyphosate (1.08 mM ) completely inhibited asexual stages of the D6 clone in vitro, and both PABA and FA antagonized the inhibitory effect of glyphosate. D6 is a clone from the African Sierra I/UNC isolate, which is sensitive to chloroquine and pyrimethamine. PABA was 1000-fold more effective than FA. B, Glyphosate inhibition of C. parvum growth. Glyphosate and paromomycin (PRM) each inhibited parasite growth (P , :001). None of the concentrations of glyphosate were toxic to the monolayer. "Media" indicates that inhibitor was not added. Reprinted with permission from [1] . tase was partially purified and shown to be heat labile, indicating that it is similar to the type I dehydroquinate dehydratases found in higher plants [20] . Previous studies using crude extract of P. falciparum detected shikimate kinase (4 mU/mg protein), 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) synthase (4 mU/mg protein), and shikimate dehydrogenase (90 mU/mg protein) [21] . Thus, there is now evidence for the presence in apicomplexan parasites of all of the shikimate pathway enzymes except 3-dehydroquinate synthase.
Chorismate synthase genes of 2 apicomplexan parasites, T. gondii and P. falciparum, have been identified and sequenced (GenBank accession numbers U 93689 and AF008549, respectively), and the sequence of P. vivax was recently completed (GenBank accession number AF451277). The deduced amino acid sequences share all the amino acids known to be highly conserved and have considerable identity with each other and the chorismate synthases from other species. However, both the T. gondii and P. falciparum proteins differ from other known chorismate synthases in possessing a number of unique insertions (figure 4). We have also recently identified homologous genes in C. parvum and E. bovis by Southern blotting with a probe derived from the T. gondii chorismate synthase cDNA (Johnson J, Roberts CW, McLeod R; unpublished data).
In addition to cloning and sequencing the T. gondii and P. falciparum chorismate synthase genes, using cDNA, we have completed the sequencing of the T. gondii genomic aroC (chorismate synthase) gene and have identified the P. falciparum genomic aroC sequence on chromosome 11 in the ongoing P. falciparum genome project (Kirisits M, Roberts CW, McLeod R, et al.; unpublished data). The T. gondii gene has many introns, but the P. falciparum sequence has none (Kirisits M, Roberts CW, McLeod R, et al.; unpublished data) [22] . Of interest, the 5 0 non-coding region of T. gondii aroC contains a potential GCN4 binding motif (TGACTC). The possible significance of this is discussed below in the section on Regulation of the Shikimate Pathway. We have determined that the T. gondii chorismate synthase gene (aroC) is single copy, which makes it amenable to gene deletion experiments, which are in progress.
Phylogeny and Subcellular Location of the Shikimate Pathway in Apicomplexan Parasites
Presence of an apicomplexan algal plastid-like organelle [23] [24] [25] and nuclear-encoded enzymes translocated and functioning in plant plastids (reviewed in [26] ) initially provided a conceptual basis for our work [27, 28] . Phylogenetic analysis of the T. gondii and P. falciparum chorismate synthases, using parsimony and distance [28] and maximum likelihood [29] analyses, indicated a puzzling monophylogeny of apicomplexan and fungal enzymes, whereas other apicomplexan nuclear genes have been located in the clade with alveolata, which in turn is aligned with ciliates and plants [30] , and plastid genes and nuclear genes targeted to the plastid have been aligned with cyanobacteria and algae [23, [31] [32] [33] . Thus, these phylogenetic analyses do not provide information that is useful for determining subcellular localization of the pathway. Fitzpatrick et al. [22] interpreted their immunofluorescence data as demonstrating cytosolic localization of P. falciparum chorismate synthase. Definitive data are needed to accurately characterize phylogeny and subcellular localization of each of the shikimate pathway enzymes.
Potential Branches Derived from the Shikimate Pathway in Apicomplexans
In plants, bacteria, and fungi, chorismate is used as a substrate for the production of many end products, including ubiquinone and the aromatic amino acids tryptophan, tyrosine, and phenylalanine. The possible role of the shikimate pathway in supplying chorismate for the synthesis of ubiquinone and aromatic amino acids in apicomplexan parasites remains to be confirmed. It has been demonstrated that treatment of human fibroblasts with interferon-g induces degradation of tryptophan and thus prevents the growth of intracellular T. gondii tachyzoites [34, 35] . Moreover, transfection of T. gondii tachyzoites with the Escherichia coli trpB gene, which encodes the b subunit of tryptophan synthase, has been shown in the presence of exogenous indole to confer resistance to this effect of interferon-g [36] . Thus, T. gondii tachyzoites would appear to be dependent on exogenous tryptophan supplied through their host cell and to be incapable of synthesizing this aromatic amino acid. The bradyzoites of T. gondii have not been studied in this respect, and it is possible that they may be unable to scavenge tryptophan. In contrast to T. gondii tachyzoites, it has been reported that tryptophan is not essential for the survival of P. falciparum, although tyrosine is an essential aromatic amino acid [37] . These two amino acids are synthesized from chorismate but by divergent enzymatic pathways (figure 1). These observations suggest that certain apicomplexan parasites have independently lost different biochemical pathways from chorismate. These differences may reflect the various evolutionary pressures operative in phylogenetically related parasites living in diverse environments.
Regulation of the Shikimate Pathway
There is no published information on regulation of the shikimate pathway in apicomplexan parasites, but information from the study of bacteria, fungi, and plants provides clues to how this might occur. Understanding the regulation of the shikimate pathway in apicomplexans may furnish valuable information that will underpin therapeutic intervention.
Regulation of the shikimate pathway is complex and varies greatly between organisms. The best-studied model is E. coli, in which the shikimate pathway is regulated by controlling the abundance and activity of DAHP synthase. Regulation occurs at the protein level by feedback inhibition and at the transcriptional level by repression [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . Feedback inhibition is the major controlling factor of these two mechanisms [38] . In Saccharomyces cerevisiae, aromatic amino acid biosynthesis is under the "general control" mechanism, which enables the organism to respond to limited amino acid supply. Thus, the expression of genes encoding shikimate pathway enzymes aro3 and aro4, which encode DAHP synthase-Phe and -Tyr, respectively, and aro1, which encodes the pentafunctional arom protein (which catalyses steps 2-6 in the pathway), are regulated by the control-activator protein GCN4. This protein binds to a specific upstream promoter element (TGACTC) present in the genes it regulates, thereby controlling their expression [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] .
Starvation for amino acids also leads to increased synthesis of shikimate pathway enzymes in the plant Arabidopsis thaliana [60] . This finding shows that plants are capable of cross-pathway metabolic regulation; however, in plants the regulation of the pathway is complicated by the subcellular localization of the enzymes. The bulk of the shikimate pathway enzyme activities are located in the plastids [61] , but there is also evidence for cytosolic isoenzymes [62] . In a number of plants, such as carrot (Dauchus carota) and A. thaliana, two isoforms of DAHP synthase have been identified [63, 64] . For example, in tobacco there is a plastidic Mn 2+ -stimulated isoform of DAHP synthase and a Co 2+ -stimulated cytosolic isoform [65] . The genes encoding the plastidic form of DAHP synthase in potatoes, tobacco, tomato, and Arabidopsis species have been isolated and characterized [4] . Induced expression of the plastidic form of the enzyme has been demonstrated by wounding or pathogen attack of potato tubers [4] and elicitor treatment or light exposure of parsley cells [66] resulting in the accumulation of metabolites of the shikimate pathway. Evidence suggests this induced expression is due to increases in the levels of transcription of the specific genes since cycloheximide and actinomycin D both inhibit this induction [67] .
Two DAHP synthase isoforms are differentially expressed in A. thaliana, in which only one isoform (DHS1) was up-regulated during wounding or pathogenic attack, while the other form remained stable [64] . In tomato (Lycopersicon esculentum), two distinct genes encoding plastidic forms of DAHP synthase have been identified, and each has different expression levels in various organs [68] . Other examples of tissue-specific expression include EPSP synthase in petunia [69] and isozymes of chorismate synthase in tomato [70] .
In the photosynthetic protozoon Euglena gracilis, two forms of EPSP synthase have been identified. One is a monofunctional 60-kDa enzyme that appears to be localized to the chloroplast [71] , and the other is a domain of the multifunctional 165-kDa AROM protein, which appears to be cytosolic [72] . These two proteins are differentially expressed according to environmental conditions, with the AROM predominant in dark-grown cells but down-regulated in light-grown cells and with the monofunctional plastid-associated form undetectable in dark-grown cells but up-regulated by light [73] .
The Shikimate Pathway and Its Branches as Antimicrobial Agent Targets
The presence of the shikimate pathway in a large number of pathogenic organisms, including bacteria, fungi, and apicomplexan parasites, and its absence from mammals make it an attractive target for the development of antimicrobial agents. Each enzyme in the pathway provides a potential target, and if any of the branches (figure 1) are operative in appropriate lifecycle stages, then this potential chemotherapeutic exploitation is amplified even more. Subcellular organelle transit and translocation signals (the enzymes that cleave signal sequences) and regulatory mechanisms for the pathway also may offer potential for exploitation as targets of antimicrobial agents.
The shikimate pathway has already been exploited by the commercial herbicide glyphosate, an inhibitor of EPSP synthase. The presence of this pathway in a wide range of pathogenic organisms, including bacteria, fungi, and apicomplexan parasites, emphasizes the potential of targeting the pathway in these organisms. Glyphosate inhibits the growth of both gram-negative and -positive bacteria in vitro [74] [75] [76] [77] . Certain bacterial chorismate synthases, DHFRs, and chorismate mutases also have been shown to be essential [1, 4] .
Although relatively high concentrations of glyphosate are required to restrict the growth of the apicomplexan parasites tested so far, the results provide impetus for the development of new anti-shikimate pathway therapies. The relatively high concentration of glyphosate required raises the important question of whether it is possible to alter the structure of glyphosate to make better inhibitors. Extensive testing of glyphosate analogues [78] has not provided compounds that are as effective as glyphosate for the inhibition of EPSP synthase. These empiric findings led Mousdale et al. [78] to suggest that glyphosate maybe a unique "toxophore" (i.e., that it may not be possible to improve upon the way this small and simple molecule interacts with EPSP synthase). The findings of McRobert and McConkey [79] suggest that inhibition of chorismate synthase is lethal for P. falciparum. The ultimate goal of inhibiting the shikimate pathway is assisted by a number of studies that have resulted in the development of an array of compounds, including various substrate analogues, capable of interfering with various steps in this pathway [2] . Most of these inhibitory activities have been demonstrated by use of assays using recombinant or purified enzymes or crude homogenates of organisms; however, some inhibitors have been assessed by their ability to inhibit the pathogen in vitro or in vivo.
A range of compounds inhibit EPSP synthase activity, such as various analogues of its substrate, shikimate 3-phosphate [80] [81] [82] [83] . The role of these compounds as potential antimicrobials has not been fully examined even though many of the compounds were found to be active at low micromolar or even nanomolar levels. Other enzymes in the shikimate pathway are also amenable to inhibition. The fluorine-containing analogue of phosphoenol pyruvate acts as a substrate for DAHP synthase, the first enzymatic step in the shikimate pathway [84] . The maximum rate at which DAHP synthase can convert this competitive inhibitor to the fluorine-containing analogue of DAHP is only about 1% that for phosphoenol pyruvate. Similarly, substrate analogues of DAHP are competitive inhibitors of dehydroquinate synthase, the second enzymatic step [85, 86] .
Substrate analogues of other shikimate pathway enzymes also inhibit the shikimate pathway. Some of these analogues do not inhibit their immediate enzyme, but are converted to substrate analogues for subsequent enzymes in the pathway. For example, in E. coli, (6S)-6-fluoroshikimate and (6R)-6-fluoroshikimate are substrates for shikimate kinase and are converted to (6S)-6-fluoro-EPSP and (6R)-6-fluoro-EPSP, respectively [10] . Whereas (6R)-6-fluoro-EPSP is an inhibitor of chorismate synthase, (6S)-6-fluoro-EPSP is slowly converted by chorismate synthase to form 6-fluorochorismate [87, 88] . This 6-fluorochorismate would appear to inhibit 4-aminobenzoic acid synthesis and account for the ability of this compound to inhibit E. coli in vitro [10, 89] . Of interest, 6-fluorochorismate can inhibit chorismate synthase of Neurospora crassa [90] . The difference observed between the E. coli and N. crassa systems may be due to the bifunctional nature of the N. crassa enzyme and may suggest that 6-fluoroshikimate interferes with the flavin reductase activity present on the N. crassa enzyme.
(6S)-6-fluoroshikimate protects mice from intraperitoneal infection with E. coli, Pseudomonas aeruginosa, and S. aureus; however, spontaneous resistance occurred at a high frequency to this compound, preventing its development for clinical use [10] . More recently, (6R) and (6S)-6-fluoroshikimic acid have each been shown to inhibit the growth of P. falciparum in vitro (IC 50 of 1:5 £ 10 25 and 2:7 £ 10 24 M, respectively) [2] . The relatively low IC 50 s of these compounds against P. falciparum highlight the potential of rationally designed substrate analogues of this pathway in the treatment of disease caused by apicomplexan parasites.
Development of Resistance to Inhibitors
A potential concern for all new drugs is the development of drug resistance. Although glyphosate tolerance has not been a problem in the field, it is possible to artificially produce glyphosate tolerance in plants and bacteria. Glyphosate-tolerant plants have been obtained by selecting tolerant cell lines while increasing the concentration of glyphosate in growth media [91] . Glyphosate-tolerant bacterial cell lines have been produced by mutagenesis [92] . These organisms have made it possible to study glyphosate resistance, an important biological mechanism with implications in medicine and agriculture.
Two different mechanisms to overcome EPSP synthase inhibition by glyphosate have been identified. The first of these is the production of glyphosate-tolerant mutant EPSP synthase. In Salmonella typhimurium, a single amino acid substitution of proline to serine at amino acid position 101 in EPSP synthase is sufficient to confer resistance to glyphosate, and it is transferable to E. coli via a cosmid [93] . In Klebsiella pneumoniae, substitution of glycine-96 with alanine in EPSP synthase reduces sensitivity to glyphosate [94] .
The second mechanism of resistance is the production of elevated levels of EPSP synthase activity. For example, in the higher plant Corydalis sempervirens, glyphosate-resistant cells have a 40-fold increase in EPSP synthase activity, while levels of the other shikimate pathway enzymes remain the same as in wild-type plants [95] . Similarly in a glyphosate-tolerant Petunia hybridoma cell line, EPSP synthase activity is increased 15-to 20-fold [96] . This increase in activity may be the result of increased gene expression, as in C. sempervirens [97] , or by gene amplification, as has been demonstrated in petunia [98] , carrot [99] , and tobacco [100] . While the adaptive mechanism appears to be the more common in plants and fungi, studies of glyphosate resistance in E. gracilis have demonstrated that either mechanism may occur [101] .
Resistance to fluoroshikimate occurs spontaneously in E. coli. This resistance correlates with a reduced ability to take up shikimate and has been mapped at or near shiA, which is one of at least two loci that determine shikimate uptake in E. coli [102] . Other shikimate-like inhibitors might suffer from the same problems, making altering modes of entry or "non-shikimate"-like inhibitors more promising strategies.
Conclusions
Characterization of the shikimate pathway in apicomplexan parasites may provide opportunities for the development of new antimicrobial agents. The inhibitor studies that use glyphosate demonstrate empirically that inhibition of EPSP synthase, and thus the shikimate pathway, is an effective means of inhibiting the growth of T. gondii, P. falciparum, and C. parvum. In a similar manner, the ability of (6R)-6-fluoroshikimate to inhibit P. falciparum suggests that inhibition of chorismate synthesis is another effective means for controlling the growth of at least P. falciparum. Increasing our understanding of the shikimate pathway in apicomplexans may not be only of biologic interest-it may expedite the discovery and design of new antimicrobial agents.
Many opportunistic pathogens, such as Pneumocystis carinii [103] , M. tuberculosis [104] , C. parvum, and T. gondii simultaneously infect AIDS patients and rely on the shikimate pathway. It is therefore possible that a single compound that inhibits the shikimate pathway or combinations of synergistic compounds that inhibit various enzyme targets in this and interrelated pathways [58, 105] could simultaneously eliminate multiple pathogens infecting a patient. Thus, they could reduce or eliminate the problems of antimicrobial agent resistance.
A recent description of bacterial genomics and targets in the shikimate pathway highlights and discusses the enzymes in the shikimate and other pathways that are particularly promising targets [105] . For apicomplexans, to date, EPSP synthase, chorismate synthase, and DHFR are the validated targets, but no data yet indicate a particular protein as favored, and much interesting work remains to be accomplished.
